We maintain our fair value estimate of $187 per share. Xywav (for excessive daytime sleepiness), Epidiolex (for childhood epilepsy), and Rylaze (for leukemia) have continued to be Jazz’s primary ...

SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...

SpringWorks Therapeutics is the perfect case study for rescuing a discontinued assets. It’s time to repeat the process for ...

The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ...

Pfizer appoints Patrizia Cavazzoni as chief medical officer, the U.S. delays the definition of 'healthy' on labels, issues ...

Pfizer has appointed former Patrizia Cavazzoni, MD, former director of the FDA's Center for Drug Evaluation and Research, as its new chief medical officer, Bloomberg reported Feb. 24. Dr. Cavazzoni, ...

Recent developments in the health sector include Pfizer appointing Patrizia Cavazzoni as Chief Medical Officer and Amgen ...

Pfizer Inc. appointed the Food and Drug Administration’s former top drug reviewer to serve as its chief medical officer.

HHS secretary RFK Jr. said that he would “shut the revolving door to reestablish public trust” in the department.

The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...

The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...